These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 24045596

  • 1. Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review.
    Wells MM, Roth LS, Marotta P, Levstik M, Mason AL, Bain VG, Chandok N, Aljudaibi BM.
    Saudi J Gastroenterol; 2013; 19(5):223-9. PubMed ID: 24045596
    [Abstract] [Full Text] [Related]

  • 2. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
    Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M.
    Biomed Pharmacother; 2011 Jul; 65(4):303-6. PubMed ID: 21723079
    [Abstract] [Full Text] [Related]

  • 3. Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection: A Retrospective Cohort Study.
    Naing C, Sitt T, Aung AT, Aung K.
    Medicine (Baltimore); 2015 Jul; 94(30):e1234. PubMed ID: 26222859
    [Abstract] [Full Text] [Related]

  • 4. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [Abstract] [Full Text] [Related]

  • 5. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L, Rimola A, Manzardo C, Valdivieso A, Montero JL, Barcena R, Abradelo M, Xiol X, Aguilera V, Salcedo M, Rodriguez M, Bernal C, Suarez F, Antela A, Olivares S, Del Campo S, Laguno M, Fernandez JR, de la Rosa G, Agüero F, Perez I, González-García J, Esteban-Mur JI, Miro JM, FIPSE LT-HIV Investigators.
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [Abstract] [Full Text] [Related]

  • 6. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.
    J Manag Care Pharm; 2013 Jan; 19(6):448-53. PubMed ID: 23806058
    [Abstract] [Full Text] [Related]

  • 7. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
    von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Häussinger D, Herrmann E, Zeuzem S.
    Gastroenterology; 2005 Aug; 129(2):522-7. PubMed ID: 16083709
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites.
    Yu S, Douglass JM, Qualls C, Arora S, Dunkelberg JC.
    Am J Gastroenterol; 2009 Jul; 104(7):1686-92. PubMed ID: 19436272
    [Abstract] [Full Text] [Related]

  • 10. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
    Faisal N, Mumtaz K, Marquez M, Renner EL, Lilly LB.
    Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
    [Abstract] [Full Text] [Related]

  • 11. Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.
    Huang CI, Huang CF, Huang JF, Dai CY, Yeh ML, Hsieh MY, Lin ZY, Chen SC, Wang LY, Yu ML, Chuang WL.
    J Gastroenterol Hepatol; 2014 May; 29(5):1012-8. PubMed ID: 24325201
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.
    Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Fukui H, Hijioka T, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Hosui A, Miyagi T, Ishida H, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.
    J Gastroenterol; 2011 Aug; 46(8):1031-7. PubMed ID: 21538029
    [Abstract] [Full Text] [Related]

  • 13. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.
    Zhou YQ, Wang XH, Hong GH, Zhu Y, Zhang XQ, Hu YJ, Mao Q.
    J Viral Hepat; 2011 Aug; 18(8):595-600. PubMed ID: 21105968
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
    Li MH, Chen LJ, Qiu GH, Lu Y, Xie Y, Xu DZ.
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
    [Abstract] [Full Text] [Related]

  • 17. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H, Abe H, Seki N, Sugita T, Aida Y, Itagaki M, Sutoh S, Shimada N, Furihata T, Tsubota A, Aizawa Y.
    World J Gastroenterol; 2015 Apr 07; 21(13):3904-11. PubMed ID: 25852275
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR, Zhang X, Yang ZG, Li P, Gao L, Chen XH, Wang J, Xiong X, Wang SM, Geng JB, Hao KY, Xie F, Wang M, Zheng WK.
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar 20; 24(3):175-80. PubMed ID: 27095759
    [Abstract] [Full Text] [Related]

  • 20. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, Shebl FM, Amer AM, Butt MT, Yakoob R, John A, Al Mohanadi M, Al Khinji MA.
    J Viral Hepat; 2008 Aug 20; 15(8):591-9. PubMed ID: 18482284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.